Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Medtronic Heart Valves
Sponsor:
Information provided by (Responsible Party):
Medtronic Heart Valves
ClinicalTrials.gov Identifier:
NCT01762124
First received: November 30, 2012
Last updated: July 9, 2014
Last verified: July 2014
  Purpose

The purpose of this early feasibility study is to determine how a new transcatheter pulmonary valve will move and perform once implanted in the right ventricular outflow tract.


Condition Intervention
Congenital Heart Disease
Tetralogy of Fallot
Device: Native Outflow Tract Transcatheter Pulmonary Valve

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Native Outflow Tract Transcatheter Pulmonary Valve Research Clinical Study

Resource links provided by NLM:


Further study details as provided by Medtronic Heart Valves:

Primary Outcome Measures:
  • Measurement of radial, linear and axial compression, bending and torsion of device [ Time Frame: 4 Days Post-Implant ] [ Designated as safety issue: No ]
    The following variables will be measured: radial compression, linear compression, axial compression, device bending and device torsion using the discharge CT. The degree of deformation of the device will be reported.


Secondary Outcome Measures:
  • Number of Patients with Procedural Success [ Time Frame: 24 hours post-implant ] [ Designated as safety issue: Yes ]
    The number of patients who are successfully implanted with the device will be reported. This is measured by meeting all of the following criteria: Confirmation that the device is fixated within the desired location, RV-PA peak-to-peak gradient is less than 25 mmHg, Pulmonary regurgitation is moderate or less, and the subject is free of explantation at 24 hours post-implant.

  • Number of Patients with Serious Procedural Adverse Events [ Time Frame: Through 5 year follow-up ] [ Designated as safety issue: Yes ]
    The number of patients that experience a serious procedural adverse event, as defined per the study protocol, will be reported.

  • Number of Patients with Device-related Adverse Events [ Time Frame: Through 5 years ] [ Designated as safety issue: Yes ]
    The number of patients that experience a device-related adverse event, as defined per the study protocol, will be reported.

  • Number of Patients with Stent Fracture [ Time Frame: Through 5 years ] [ Designated as safety issue: Yes ]
    The number of patients that experience a stent fracture of their device will be reported.

  • Number of Patients with Catheter Re-intervention on the TPV [ Time Frame: Through 5 years ] [ Designated as safety issue: Yes ]
    The number of patients that experience a catheter re-intervention will be reported.

  • Assessment of Surgical Intervention on the TPV [ Time Frame: Through 5 years ] [ Designated as safety issue: Yes ]
    The number of patients that undergo a surgical intervention will be reported.

  • Number of Patient Deaths (all-cause, procedural, and device-related) [ Time Frame: Through 5 years ] [ Designated as safety issue: Yes ]
    Any patient deaths that occur during the study will be reported.

  • Pulmonary Regurgitant Fraction (%) as measured by cardiac MRI [ Time Frame: Through 5 years ] [ Designated as safety issue: No ]
    The pulmonary regurgitant fraction for all patients, as measured by cardiac MRI, will be reported.

  • Pulmonary Regurgitation Severity as Measured by Echocardiography [ Time Frame: Through 5 years ] [ Designated as safety issue: No ]
    The pulmonary regurgitation severity for all patients, as measured by echocardiography, will be reported.

  • Right Ventricular Volume (ml) as Measured by Cardiac MRI [ Time Frame: Through 5 years ] [ Designated as safety issue: No ]
    The right ventricular volumes for all patients, as measured by cardiac MRI, will be reported.

  • Mean RVOT Gradient (mmHg) as Measured by Color Wave Doppler [ Time Frame: Through 5 years ] [ Designated as safety issue: No ]
    The mean RVOT gradient for all patients, as measured by Color Wave Doppler, will be reported.


Estimated Enrollment: 20
Study Start Date: October 2012
Estimated Study Completion Date: February 2020
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Native Outflow Tract TPV Device: Native Outflow Tract Transcatheter Pulmonary Valve
Other Names:
  • Native Outflow Tract TPV
  • Native TPV

Detailed Description:

Medtronic, Inc. is in the process of developing a novel transcatheter device option for patients with congenital heart disease, without right ventricle-to-pulmonary artery conduits, called the Native Outflow Tract Transcatheter Pulmonary Valve. Given limitations in the animal model to confirm device boundary conditions, this feasibility study is proposed to characterize that information as well as evaluate safety, procedural feasibility and performance data to be used for future development of the device.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has pulmonary regurgitation as per one or more of the following criteria: Severe pulmonary regurgitation as measured by Doppler echocardiography, or Pulmonary regurgitant fraction ≥ 30% as measured by cardiac magnetic resonance imaging
  • Clinical indication for surgical placement of a RVOT conduit or bioprosthetic pulmonary valve per one or more of the following criteria: Subject is symptomatic secondary to pulmonary insufficiency (e.g. exercise intolerance, fluid overload) as classified by the Investigator, or Right ventricular end diastolic volume (RVEDV) ≥ 150 ml/m2
  • Subject is willing to consent to participate in the study and will commit to completion of all follow-up requirements

Exclusion Criteria:

  • Anatomy unable to accommodate a 25 Fr delivery system
  • Obstruction of the central veins
  • Clinical or biological signs of infection including active endocarditis
  • Indicated for intervention of stenosis of the branch pulmonary arteries at time of implant
  • Positive pregnancy test at baseline (prior to CT angiography and again prior to implant procedure) in female subjects of child bearing potential
  • Patients with right ventricular outflow tract obstruction (RVOTO) lesions surgically treated with a right ventricle-to-pulmonary artery conduit implant
  • A major or progressive non-cardiac disease (e.g. liver failure, renal failure, cancer) that results in a life expectancy of less than one year
  • Planned implantation of the Native Outflow Tract TPV in the left heart
  • RVOT anatomy or morphology that is unfavorable for anchoring
  • Known allergy to aspirin, heparin, or nickel
  • Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
  • Pre-existing prosthetic heart valve or prosthetic ring in any position
  • Patient is currently enrolled in another investigational device or drug trial that may influence the outcome of this trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01762124

Contacts
Contact: Krissy Dockery 800-633-8766 ext 6-3095 kristin.m.dockery@medtronic.com
Contact: Medtronic Cardiovascular Lifeline 877-526-7890 rs.cstechsupport@medtronic.com

Locations
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: James E. Lock, MD    617-355-7313      
Principal Investigator: James E. Lock, MD         
United States, Ohio
Nationwide Children's Hospital Recruiting
Columbus, Ohio, United States, 43205
Contact: John P. Cheatham, MD    614-722-2459    john.cheatham@nationwidechildrens.org   
Principal Investigator: John P. Cheatham, MD         
Canada, Ontario
The Hospital for Sick Children Recruiting
Toronto, Ontario, Canada, M5G 1X8
Contact: Lee Benson, MD    (416) 813-6141    lee.benson@sickkids.ca   
Principal Investigator: Lee Benson, MD         
Sponsors and Collaborators
Medtronic Heart Valves
Investigators
Principal Investigator: Lee Benson, MD The Hospital for Sick Children, Toronto, Canada
Principal Investigator: John P. Cheatham, MD Nationwide Children's Hospital, Columbus, Ohio, USA
Principal Investigator: James E Lock, MD Boston Children's Hospital, Boston, Massachusetts, USA
  More Information

No publications provided

Responsible Party: Medtronic Heart Valves
ClinicalTrials.gov Identifier: NCT01762124     History of Changes
Other Study ID Numbers: 10022972DOC
Study First Received: November 30, 2012
Last Updated: July 9, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Medtronic Heart Valves:
Pulmonary valve
Congenital heart disease
Transcatheter pulmonary valve
Percutaneous pulmonary valve

Additional relevant MeSH terms:
Heart Diseases
Heart Defects, Congenital
Tetralogy of Fallot
Cardiovascular Diseases
Cardiovascular Abnormalities
Congenital Abnormalities

ClinicalTrials.gov processed this record on October 19, 2014